Cell-free DNA in cancer

current insights

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Background: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology. Conclusions: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.

Original languageEnglish
Pages (from-to)13-28
Number of pages16
JournalCellular Oncology
Volume42
Issue number1
DOIs
Publication statusPublished - 15 Feb 2019

Keywords

  • cancer
  • Cell-free DNA
  • Circulating tumour DNA
  • liquid biopsy

Cite this

@article{1a6796d9ad1a4efb990e2a11e3262d50,
title = "Cell-free DNA in cancer: current insights",
abstract = "Background: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology. Conclusions: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.",
keywords = "cancer, Cell-free DNA, Circulating tumour DNA, liquid biopsy",
author = "Heidi Fettke and Kwan, {Edmond M.} and Azad, {Arun A.}",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s13402-018-0413-5",
language = "English",
volume = "42",
pages = "13--28",
journal = "Cellular Oncology",
issn = "2211-3428",
publisher = "Springer-Verlag London Ltd.",
number = "1",

}

Cell-free DNA in cancer : current insights. / Fettke, Heidi; Kwan, Edmond M.; Azad, Arun A.

In: Cellular Oncology, Vol. 42, No. 1, 15.02.2019, p. 13-28.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Cell-free DNA in cancer

T2 - current insights

AU - Fettke, Heidi

AU - Kwan, Edmond M.

AU - Azad, Arun A.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Background: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology. Conclusions: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.

AB - Background: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology. Conclusions: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.

KW - cancer

KW - Cell-free DNA

KW - Circulating tumour DNA

KW - liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85055942702&partnerID=8YFLogxK

U2 - 10.1007/s13402-018-0413-5

DO - 10.1007/s13402-018-0413-5

M3 - Review Article

VL - 42

SP - 13

EP - 28

JO - Cellular Oncology

JF - Cellular Oncology

SN - 2211-3428

IS - 1

ER -